European stocks fell yesterday, trimming last week’s lofty gains as concern over events in Ukraine and China’s flagging manufacturing activity pegged a key index back from the top of its recent range.

Shares of companies with big exposure to Russia were under pressure as the US began crisis talks with European allies over Ukraine.

Finnish tyremaker Nokian Renkaat was down 2.1 per cent, Austrian lender Raiffeisen Bank International down two per cent and Danish brewer Carlsberg down 0.6 per cent. The three firms derive about 26 per cent, 22 per cent and 17 per cent respectively of their revenues from Russia, according to data from MSCI.

While the developments did not mark a severe setback, confirmation that geopolitical uncertainty would continue into a fourth week was enough to see European shares retrace some of last week’s gains.

The FTSEurofirst 300 gained 1.8 per cent last week, buoyed by assurances from Russia that it would not intervene in the affairs of any other regions in Ukraine.

“Geopolitical tensions have eased somewhat... but the market remains susceptible to negative headlines,” Atif Latif, director of trading at Guardian Stockbrokers, said, highlighting the withdrawal of Ukrainian troops from Crimea and a build-up of Russian troops on the border.

Nato’s top military commander said on Sunday that Russia had built up a “very sizeable” force on its border with Ukraine, and that Moscow may have a region in another ex-Soviet republic, Moldova, in its sights.

The FTSEurofirst 300 closed down one per cent at 1,293.73 points, bringing it back from the top end of the 125-point range it has traded in for the last five sessions.

“The equity market’s long-term trend is still positive,” Barclays France director Franklin Pichard said. “But in the short term, indexes could remain stuck in this consolidation zone and within tight ranges.”

Shares in Bayer were among the biggest European blue-chip losers, down 3.3 per cent after Britain’s healthcare cost agency recommended the state health service not use the firm’s new prostate cancer drug Xofigo.

Also under pressure were industrials, after China’s flash Markit/HSBC Purchasing Managers’ Index (PMI) fell to an eight-month low of 48.1 in March, a weaker-than-expected figure. The index has been below the 50 level since January, indicating a contraction in the sector this year.